CYP2D6 and CYP2C19 Genotyping in Psychiatric Patients on Psychotropic Medication in the Former Dutch Antilles

References

• Nelson DR , KoymansL , KamatakiTet al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature . Pharmacogenetics6 ( 1 ), 1 – 42 ( 1996 ).
   PubMedGoogle Scholar
• Fleeman N , DundarY , DicksonR , JorgensenA , PushpakomS , McleodC . Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses . Pharmacogenomics J.11 , 1 – 14 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M . Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future . Trends Pharmacol. Sci.25 ( 4 ), 193 – 200 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• van der Weide J , HinrichsJWJ . The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications . Clin. Biochem. Rev.27 ( 1 ), 17 – 25 ( 2006 ).
   PubMedGoogle Scholar
• Arranz MJ , de LeonJ . Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research . Mol. Psychiatry.12 ( 8 ), 707 – 747 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Van Der Weide J , SteijnsLSW . Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology . Ann. Clin. Biochem.36 , 722 – 729 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Fleeman N , McLeodC , BagustAet al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation . Health Technol. Assess.14 ( 3 ), 1 – 157 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Brockmöller J , KirchheinerJ , SchmiderJet al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment . Clin. Pharmacol. Ther.72 ( 4 ), 438 – 52 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Van Der Weide J , Van Baalen-benedekEH , Kootstra-rosJE . Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype . Ther. Drug Monit.27 ( 4 ), 478 – 483 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Suzuki T , MiharaK , NakamuraAet al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia . Ther. Drug Monit.33 ( 1 ), 21 – 24 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Schenk PW , van VlietM , MathotRAet al. The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients . Pharmacogenomics J.10 ( 3 ), 219 – 25 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Hiemke C , BaumannP , BergemannNet al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011 . Pharmacopsychiatry44 ( 1 ), 195 – 235 ( 2011 ).
   Google Scholar
• de Haan L , van BruggenM , LavalayeJ , BooijJ , DingemansPMAJ , LinszenD . Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study . Am. J. Psychiatry160 ( 2 ), 303 – 309 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Nikoloff D , ShimJ , PattenNet al. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics . Pharmacogenomics J.2 , 400 – 407 ( 2002 ).
   PubMedGoogle Scholar
• Kapitany T , MeszarosK , LenzingerEet al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia . Schizophr. Res.32 ( 2 ), 101 – 106 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Patsopoulos NA , NtzaniEE , ZintzarasE , IoannidisJPA . CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis . Pharmacogenet. Genomics15 ( 3 ), 151 – 158 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Scordo MG , SpinaE , RomeoPet al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients . Eur. J. Clin. Pharmacol.56 ( 9–10 ), 679 – 683 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Laika B , LeuchtS , HeresS , SteimerW . Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?Pharmacogenomics J.9 ( 6 ), 395 – 403 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Schillevoort I , de BoerA , van der WeideJet al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case–control study . Pharmacogenetics12 ( 3 ), 235 – 240 ( 2002 ).
   PubMedGoogle Scholar
• Hiroi T , ImaokaS , FunaeY . Dopamine formation from tyramine by CYP2D6 . Biochem. Biophys. Res. Commun.249 ( 3 ), 838 – 843 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Llerena A , EdmanG , GobaledaJ , BenitzJ , SchallingD , BertilssonL . Relationship between personality and debrisoquine hydroxylation capacity . Acta Psychiatr. Scand.87 , 23 – 28 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Llerena A , DoradoP , Peñas-LledóEM , CáceresMC , De la RubiaA . Low frequency of CYP2D6 poor metabolizers among schizophrenia patients . Pharmacogenomics J.7 ( 6 ), 408 – 410 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Rasmussen JO , ChristensenM , SvendsenJM , SkausigO , HansenEL , NielsenKA . CYP2D6 gene test in psychiatric patients and healthy volunteers . Scand. J. Clin. Lab. Invest.66 ( 2 ), 129 – 36 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Chen CH , HungCC , WeiFC , KoongFJ . Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan . Psychiatr. Genet.11 ( 3 ), 153 – 155 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Cai W-M , NikoloffDM , PanR-Met al. CYP2D6 genetic variation in healthy adults and psychiatric African–American subjects: implications for clinical practice and genetic testing . Pharmacogenomics J.6 ( 5 ), 343 – 350 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Dawson E , PowellJF , NöthenMMet al. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia . Psychiatr. Genet.4 ( 4 ), 215 – 218 ( 1994 ).
   PubMedGoogle Scholar
• Pirmohamed M , WildMJ , KitteringhamNRet al. Lack of association between schizophrenia and the CYP2D6 gene polymorphisms . Am. J. Med. Genet.67 ( 2 ), 236 – 237 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Jönsson EG , DahlML , RohHK , JerlingM , SedvallGC . Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia . Psychiatr Genet.8 ( 1 ), 25 – 28 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Daniels J , WilliamsJ , AshersonP , McGuffinP , OwenM . No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT) . Am. J. Med. Genet.60 ( 27 ), 85 – 87 ( 1995 ).
   PubMedGoogle Scholar
• Bradford LD . CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants . Pharmacogenomics3 ( 2 ), 229 – 243 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Dahl ML , JohanssonI , BertilssonL , Ingelman-SundbergM , SjöqvistF . Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis . J. Pharmacol. Exp. Ther.274 ( 1 ), 516 – 520 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Agúndez JAG , LedesmaMC , LaderoJM , BenítezJ . Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population . Clin. Pharmacol. Ther.57 ( 3 ), 265 – 269 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity . Pharmacogenomics J.5 ( 1 ), 6 – 13 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Aklillu E , PerssonI , BertilssonL , JohanssonI , RodriguesF , Ingelman-SundbergM . Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles . J. Pharmacol. Exp. Ther.278 ( 1 ), 441 – 446 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , BradfordLD , MarcucciKA , LeederJS . Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans . Clin. Pharmacol. Ther.72 ( 1 ), 76 – 89 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Moreno-Estrada A , GravelS , ZakhariaFet al. Reconstructing the population genetic history of the Caribbean . PLoS Genet.9 ( 11 ), e1003925 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Céspedes-Garro C , NaranjoM-EG , Rodrigues-SoaresFet al. Pharmacogenetic research activity in Central America and the Caribbean: a systematic review . Pharmacogenomics17 ( 15 ), 1707 – 1724 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• van Harten PN , MatroosGE , HoekHW , KahnRS . The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curaçao Extrapyramidal Syndromes Study: I . Schizophr. Res.26 ( 2–3 ), 195 – 203 ( 1996 ).
   Web of Science ®Google Scholar
• Centraal Bureau voor de Statistiek Den Haag . http://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=37325&D1=0&D2=a&D3=0&D4=0&D5=0-4,155,157&D6=a&HDR=G3,G2,G4&STB=G1,T,G5&VW=T .
   Google Scholar
• Albuquerque J , RibeiroC , NaranjoMEG , LlerenaA , GrazinaM . Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications . Per. Med.10 ( 7 ), 709 – 718 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Miura J , ObuaC , AbboC , KanekoS , TateishiT . Cytochrome P450 2C19 genetic polymorphisms in Ugandans . Eur. J. Clin. Pharmacol.65 ( 3 ), 319 – 320 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ragia G , ArvanitidisKI , TavridouA , ManolopoulosVG . Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece . Pharmacogenomics10 ( 1 ), 43 – 49 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• The Human Cytochrome P450 (CYP) Allele Nomenclature Database . www.cypalleles.ki.se/ .
   Google Scholar
• The Human Cytochrome P450 (CYP) Allele Nomenclature Database . CYP2D6 allele nomenclature . www.cypalleles.ki.se/cyp2d6.htm .
   Google Scholar
• Loovers HM , van der WeideJ . Implementation of CYP2D6 genotyping in psychiatry . Expert Opin. Drug Metab. Toxicol.5 ( 9 ), 1065 – 1077 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Crews KR , GaedigkA , DunnenbergerHMet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype . Clin. Pharmacol. Ther.91 ( 2 ), 321 – 326 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Hicks JK , BishopJR , SangkuhlKet al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors . Clin. Pharmacol. Ther.98 ( 2 ), 127 – 134 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Raymond M , RoussetF . GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism . J. Hered.86 , 248 – 249 ( 1995 ).
   Web of Science ®Google Scholar
• Rousset F . genepop’007: a complete re-implementation of the genepop software for Windows and Linux . Mol. Ecol. Resour.8 ( 1 ), 103 – 106 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Montané Jaime LK , LallaA , SteimerW , GaedigkA . Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants . Pharmacogenomics14 ( 3 ), 261 – 276 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Scott SA , SangkuhlK , GardnerEEet al. Supplemental material clinical pharmacogenetics implementation consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy . Clin. Pharmacol. Ther.90 ( 2 ), 1 – 11 ( 2011 ).
   Web of Science ®Google Scholar
• Dalhuisen L , DonkR , HoefteR , SteeghF . History of the Antilles Aruba, Bonaire, Curaçao, Saba, Sint-Eustatius, Sint-Maarten (Geschiedenis van de Antillen Aruba, Bonaire, Curaçao, Saba, Sint-Eustatius, Sint-Maarten) . Walburg Pers .
   Google Scholar
• Samer CF , LorenziniKI , RollasonV , DaaliY , DesmeulesJA . Applications of CYP450 testing in the clinical setting . Mol. Diagnosis Ther.17 ( 3 ), 165 – 184 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Yin SJ , NiYB , WangSM , WangX , LouYQ , ZhangGL . Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations . J. Clin. Pharm. Ther.37 ( 3 ), 364 – 369 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• González I , Peñas-LledóEM , PérezB , DoradoP , AlvarezM , LLerenaA . Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers . Pharmacogenomics9 ( 7 ), 833 – 840 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Ruaño G , SzarekBL , VillagraDet al. Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder . Biomark. Med.7 ( 3 ), 429 – 439 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Inaba T , JorgeL , AriasT . Mephenytoin hydroxylation in the Cuna Amerindians of Panama . Br. J. Clin. Pharmacol.25 ( 1 ), 75 – 79 ( 1988 ).
   PubMed Web of Science ®Google Scholar
• Luo H , PolansR , LinK , WanY . Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study . Clin. Pharmacol. Ther.80 ( 1 ), 33 – 40 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Hicks JK , SwenJJ , ThornCFet al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants . Clin. Pharmacol. Ther.93 ( 5 ), 402 – 408 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Sim SC , NordinL , AnderssonTM-Let al. Association between CYP2C19 polymorphism and depressive symptoms . Am. J. Med. Genet. Part B Neuropsychiatr. Genet.153B , 1160 – 1166 ( 2010 ).
   PubMed Web of Science ®Google Scholar